Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Healthtrust
US Army
McKinsey
Citi
Queensland Health
Chinese Patent Office
Baxter
Accenture

Generated: December 18, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ENTOCORT EC

« Back to Dashboard

Clinical Trials for Entocort Ec

Trial ID Title Status Sponsor Phase Summary
NCT00135408 A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral Budesonide Completed Medarex Phase 2 The purpose of the study is to determine Efficacy, Safety and Tolerability of MDX-010 (BMS-734016) administered with or without Prophylactic Oral Budesonide.
NCT00135408 A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral Budesonide Completed Bristol-Myers Squibb Phase 2 The purpose of the study is to determine Efficacy, Safety and Tolerability of MDX-010 (BMS-734016) administered with or without Prophylactic Oral Budesonide.
NCT00343642 Dietary Treatment of Crohn's Disease Completed National Center for Complementary and Integrative Health (NCCIH) Phase 1/Phase 2 Our objective is to determine whether a specific dietary intervention or a fructooligosaccharide (FOS) supplement has anti-oxidant or prebiotic effects and whether it is beneficial in the treatment of Crohn's Disease (CD.
NCT00343642 Dietary Treatment of Crohn's Disease Completed Rush University Medical Center Phase 1/Phase 2 Our objective is to determine whether a specific dietary intervention or a fructooligosaccharide (FOS) supplement has anti-oxidant or prebiotic effects and whether it is beneficial in the treatment of Crohn's Disease (CD.
NCT00679380 (CB-01-02/02) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis Completed Cosmo Technologies Ltd Phase 3 This will be a multicentre, randomised, double-blind, double-dummy, parallel group comparative study in patients with mild or moderate, active ulcerative colitis. The study will compare budesonide-MMX™ 6 mg and budesonide-MMX™ 9 mg tablets to placebo and to Entocort® 3 x 3 mg capsules, in four parallel groups of patients over an 8 week treatment period. After the screening visit, patients will enter a washout period of 2 days, then they will be randomised to the following four treatment groups: budesonide-MMX™ tablets (6 mg), budesonide-MMX™ tablets (9 mg), Entocort® capsules (3 x 3 mg) and placebo (tablets and capsules), all administered once a day after breakfast. Hence, each patient will receive, in the morning after breakfast, either one budesonide-MMX™ 6 mg or budesonide MMX™ 9 mg tablet and 3 placebo Entocort® matching capsules, or three Entocort® 3 mg capsules and one placebo budesonide-MMX™ matching tablet, or one placebo budesonide-MMX™ matching tablet and three placebo Entocort® matching capsules.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Entocort Ec

Condition Name

Condition Name for Entocort Ec
Intervention Trials
Crohn's Disease 3
Inflammatory Bowel Disease 2
Ulcerative Colitis 2
Malignant Melanoma 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Entocort Ec
Intervention Trials
Crohn Disease 3
Ulcer 2
Colitis, Ulcerative 2
Colitis 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Entocort Ec

Trials by Country

Trials by Country for Entocort Ec
Location Trials
United States 24
Canada 5
Poland 5
Italy 4
United Kingdom 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Entocort Ec
Location Trials
New York 3
Illinois 3
Georgia 3
New Jersey 2
Minnesota 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Entocort Ec

Clinical Trial Phase

Clinical Trial Phase for Entocort Ec
Clinical Trial Phase Trials
Phase 4 1
Phase 3 3
Phase 2 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Entocort Ec
Clinical Trial Phase Trials
Completed 5
Terminated 2
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Entocort Ec

Sponsor Name

Sponsor Name for Entocort Ec
Sponsor Trials
Perrigo Company 2
Valeant Pharmaceuticals International, Inc. 1
National Institutes of Health Clinical Center (CC) 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Entocort Ec
Sponsor Trials
Industry 7
Other 3
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
US Department of Justice
Cipla
Cantor Fitzgerald
Mallinckrodt
Julphar
Boehringer Ingelheim
AstraZeneca
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.